| Drug Type Small molecule drug | 
| Synonyms 10-(3-(4-Hydroxypiperidino)propyl)phenothiazine-2-carbonitrile, 2-Cyano-10-(3-(4-hydroxy-1-piperidyl)propyl)phenothiazine, 2-Cyano-10-(3-(4-hydroxypiperidino)propyl)phenothiazine + [10] | 
| Target | 
| Action antagonists | 
| Mechanism DRDs antagonists(Dopamine receptors antagonists) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhaseApproved | 
| First Approval Date Japan (07 Apr 1964),  | 
| Regulation- | 
| Molecular FormulaC21H23N3OS | 
| InChIKeyLUALIOATIOESLM-UHFFFAOYSA-N | 
| CAS Registry2622-26-6 | 
| KEGG | Wiki | ATC | Drug Bank | 
|---|---|---|---|
| - | Periciazine | 
| Indication | Country/Location | Organization | Date | 
|---|---|---|---|
| Schizophrenia | Japan  | 07 Apr 1964 | |
| Schizophrenia | Japan  | 07 Apr 1964 | 





